Professional Documents
Culture Documents
1 s2.0 S2210836X13000237 Main
1 s2.0 S2210836X13000237 Main
1 s2.0 S2210836X13000237 Main
REVIEW ARTICLE
Department of Dermatology, JN Medical College, Aligarh Muslim University (AMU), Aligarh, India
KEYWORDS Abstract Alopecia areata (AA) is a nonscarring, autoimmune hair loss on the scalp, and/or body.
Alopecia areata; Etiology and pathogenesis are still unknown. The most common site affected is the scalp in the form
Etiology; of solitary or multiple patches of alopecia. Histopathology is characterized by an increased number
Pathogenesis; of telogen follicles and presence of inflammatory lymphocytic infiltrate in the peribulbar region.
Management Corticosteroids are the most popular drugs for the treatment of this disease. This review precisely
outlines the etiologic and pathogenic mechanisms, clinical features, diagnosis and management of
alopecia areata.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
2. Dynamics of hair loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3. Etiopathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.1. Animal models in the understanding of pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2. Psychological factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4. Clinical features . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.1. Quantitating hair loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4.2. Gauging severity of disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
5. Differential diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
6. Histopathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
7. Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
7.1. Glucocorticoids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
7.1.1. Intralesional corticosteroids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
2210-836X ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.
http://dx.doi.org/10.1016/j.jssdds.2013.05.004
38 S.S. Amin, S. Sachdeva
3. Etiopathogenesis
Based on this knowledge new therapeutic options may be mal hair demarcates the periphery of the lesion (Fig. 3). The
developed such as inhibition of lymphocyte-homing by an scalp is the most common site affected by AA (90%) Tan et
anti-CD44v10 antibody, or inhibition of costimulation by al. (2002) and Camacho (1997). Scalp and body hair such as eye-
monoclonal antibodies (Freyschmidt-Paul et al., 2004). brows, eyelashes, beard, underarm hair, and pubic hair may be
Animal models have also suggested a role of vitamin A in affected (Alopecia Totalis), as well as the entire body (Alopecia
the regulation of both the hair cycle and immune response to Universalis). The ophiasis pattern refers to a severe form of AA
alter the progression of AA. Gene array in graft-induced extending along the posterior occipital and temporal scalp mar-
C3H/HeJ mice revealed that genes involved in retinoic acid gins. The affected skin appears normal with no grossly evident
(RA) synthesis were increased, whereas RA degradation genes epidermal alterations such as scaling or follicular abnormalities
were decreased in AA compared with sham controls. RA levels (Diana Draelos, 2007). In all forms ‘‘exclamation point hairs’’
were also increased in C3H/HeJ mice with AA. C3H/HeJ mice are found, that become narrower along the length of the strand
were fed a purified diet containing one of the four levels of die- closer to the base may be seen within or around the areas of alo-
tary vitamin A or an unpurified diet 2 weeks before grafting pecia (Cline, 1988). Upon regrowth, hair often initially lack pig-
and disease progression followed. High vitamin A accelerated ment resulting in blonde or white hair (Finner, 2011). Nail
AA, whereas mice that were not fed vitamin A had more severe changes can be seen in a portion of patients (10–66%) of AA.
disease by the end of the study. More hair follicles were in ana- Small shallow pits (30%) up to trachyonychia (sandpaper nails;
gen in mice fed with high vitamin A. Both the number and 10%) are typical, rarely other changes can also be seen. A red-
localization of granzyme B-positive cells were altered by vita- spotted lunula and periungual erythema have been postulated
min A. IFNc was the lowest and IL13 highest in mice fed with as a sign of acute nail involvement (Olsen, 2003).
high vitamin A. Other cytokines were reduced and chemokines
increased as the disease progressed (Duncan et al., 2013). 4.1. Quantitating hair loss
3.2. Psychological factors Hair pull tests conducted at the periphery of the lesion may be
correlated with disease activity and also assist in determining
Some studies have suggested that emotional stress contributes the etiology of alopecia. A few clinical tests are presented
to the appearance of alopecia areata, given the observation below:
that emotional trauma precedes the process (Baker, 1987) to- The pull test: this test helps to evaluate diffuse scalp hair loss.
gether with the high prevalence of psychological disorders Gentle traction is exerted on a group of hair (about 40–60) on
occurring in these patients (Colon et al., 1991). While, on the three different areas of the scalp. The number of extracted
contrary, other studies have demonstrated that there is no par- hairs is counted and examined under a microscope. Nor-
ticipation of emotional phenomena in the development of alo- mally, <3 hairs per area should come out with each pull. If
pecia areata (van der Steen et al., 1992). >10 hairs are obtained, the pull test is considered positive.
A possible explanation of the pathogenic mechanisms pro- The pluck test: In this test, the individual pulls hair out ‘‘by
voked by emotional conditions lies in the production of neu- the roots.’’ The root of the plucked hair is examined under a
romediators capable of interfering in the immunity. Some microscope to determine the phase of growth and used to
studies have revealed a decrease in the expression of calcitonin diagnose a defect of telogen, anagen, or systemic disease.
gene related peptide (CGRP) and substance P in the scalp of Telogen hairs are hairs that have tiny bulbs without sheaths
alopecia areata patients (Hordinsky et al., 1995a,b). CGRP at their roots. Telogen effluvium shows an increased per-
has an anti-inflammatory action, (Raud et al., 1991) and its de- centage of hairs upon examination. Anagen hairs are hairs
crease in alopecia areata could favor the characteristic follicu- that have sheaths attached to their roots. Anagen effluvium
lar inflammatory phenomena. Substance P is capable of shows a decrease in telogen-phase hairs and an increased
inducing hair growth in mice (Paus et al., 1994) and its de- number of broken hairs.
crease in alopecia areata could be a contributing factor to Scalp biopsy: This test is done when alopecia is present, but
the reduced proliferation of pilar follicles. the diagnosis is unsure. The biopsy allows for differing
between scarring and nonscarring forms in case there is clin-
4. Clinical features ical distinction is difficult. Hair samples are taken from areas
of inflammation, usually around the border of the bald patch.
The diagnosis of AA is essentially made on clinical grounds. Daily hair counts: This is normally done when the pull test is
Age at onset, duration and progression of disease, personal negative. It is done by counting the number of hairs lost. The
and family history of atopy, family history of similar disease hair that should be counted are the hairs from the first morn-
with special reference to autoimmune disease and other sys- ing combing or during washing. The hair is collected in a clear
temic complaints are noted in detail. Routine investigations like plastic bag for 14 days. The strands are recorded. If the hair
complete hemogram, anemia panel, erythrocyte sedimentation count is >100/day, it is considered abnormal except after
rate, thyroid function tests, serum calcium, serum proteins, shampooing, where hair counts will be up 250 and be normal.
etc. should be carried out to arrive at a specific diagnosis. Skin Trichoscopy: Trichoscopy is a non-invasive method of hair
biopsy and autoimmune panel may be performed in selected and scalp evaluation. The test may be performed with the
cases. Alopecia areata most commonly manifests as a sudden use of a hadheld dermoscope or a videodermoscope. In alo-
loss of hair in localized areas. The lesion is usually a round or pecia areata trichoscopy shows regularly distributed ‘‘yel-
oval patch of alopecia and may be solitary (Alopecia Areata low dots’’ (hyperkeratotic plugs), micro-eclamation mark
monolocularis) or numerous (Alopecia Areata multilocularis). hairs, and ‘‘black dots’’ (destroyed hairs in the hair follicle
The patch of alopecia usually has a distinct border where nor- opening.
Alopecia areata: A review 41
Nails as described earlier, show changes in the form of pit- ring alopecias have loss of follicular ostia, or atrophy. Clinical
ting or trachyonychia (Olsen et al., 2004). Stigmata of organ inflammation is frequently, but not always, present. Histologic
specific autoimmunity may be present on systemic inflammation may be present. Ultimately, histologic confirma-
examination. tion is the best method to confirm the presence of a fibrosing/
scarring process with loss of hair follicles. A few entities in
4.2. Gauging severity of disease scarring alopecias are Lichen planopilaris, Central centrifugal
cicatricial alopecia, Pseudopelade, Discoid lupus and Traction
alopecia. The main confounders in diagnosis are the other
Researchers have devised a clinical scale in order to assess the
varieties of non scarring alopecias. They are:
severity of AA (Ay Se et al., 2000), presented as follows:
Trichotillomania: this condition probably causes most con-
1 Mild: Three or less patches of alopecia with a widest diam-
fusion and it is possible that it coexists with alopecia areata
eter of <3 cm or disease limited to eyelashes and eyebrows.
in some cases. The incomplete nature of the hair loss in
2 Moderate: Existence of more than three patches of alopecia
trichotillomania and the fact that the broken hairs are
or a patch greater than 3 cm at the widest diameter without
firmly anchored in the scalp (i.e. they remain in the growing
alopecia totalis or universalis.
phase, anagen, unlike exclamation mark hairs) are distin-
3 Severe: Alopecia totalis or alopecia universalis.
guishing features.
4 Ophiasis: Severe form in which loss of hair occurs in the
Tinea capitis: the scalp is inflamed in tinea capitis and there
shape of a wave at the circumference of the head (described
is often scaling but the signs may be subtle.
above).
Early scarring alopecia.
Telogen effluvium.
The National Alopecia Areata Foundation working com-
Anagen effluvium (drug-induced) may mimic diffuse alope-
mittee has devised ‘‘Severity of Alopecia Tool score’’ (SALT
cia areata.
score) Price and Gummer, 1989. Scalp is divided into four areas
Systemic lupus erythematosus.
namely, Vertex – 40% (0.4) of scalp surface area; right profile of
Secondary syphilis.
scalp – 18% (0.18) of scalp surface area; left profile of scalp –
Loose anagen hair syndrome: This is a disorder of abnormal
18% (0.18) of scalp surface area; Posterior aspect of scalp –
anagen hair anchorage. It is commonly found in children
24% (0.24) of scalp surface area. Percentage of hair loss in
and has an autosomal dominant inheritance (Lew, 2009).
any of these areas is percentage of hair loss multiplied by per-
ADTA: Acute diffuse and total alopecia (ADTA) is a new
cent surface area of the scalp in that area. SALT score is the
subtype of alopecia areata with favorable prognosis. ADTA
sum of percentage of hair loss in all above mentioned areas.
has been reported to have a short clinical course ranging
from acute hair loss to total baldness, followed by rapid
5. Differential diagnosis
recovery, sometimes even without treatment (Garcia-Her-
nandez, 2000).
Though alopecia areata is a form of non scarring alopecia, it is SISAPHO: This is an unusual form of Alopecia, in which a
sometimes confused with different varieties of scarring alope- band-like pattern is found on the frontal hairline. This can
cia as well. This is also because many alopecia types are bipha- be clinically confused with frontal fibrosing alopecia. The
sic in their natural history. The first step, therefore is to opposite of ophiasis type, where hairs are lost centrally
distinguish between scarring and non scarring alopecias. Scar- and spared at the margins of the scalp, is called sisiapho.
It may mimic androgenetic alopecia (Ragunatha et al.,
2008).
Raunatha et al. in their case report have demonstrated
infantile scurvy also, as a cause of diffuse non scarring alopecia
of the scalp (Whiting, 2003).
6. Histopathology
Figure 5 Algorithm for management of Alopecia areata in different age groups. (*Adapted with permission from the Editor, J. Am.
Acad. Dermatol. 2010;62:191–202).
be suspected when high percentages of telogen hair or minia- treatment are often seen in 1–2 months. Additional treatments
turized hair are present, even in the absence of a peribulbar are repeated every 4–6 weeks.
lymphocytic infiltrate. The histopathology of the lesion in
ADTA reveals infiltration of mononuclear cells around the 7.1.2. Topical corticosteroids
hair follicles and prominent pigment incontinence (Garcia- Several forms of topical corticosteroids have been reported to
Hernandez, 2000). exhibit varying levels of efficacy in AA. Some of the topical
therapies have included fluocinolone acetonide cream, fluocin-
7. Management olone scalp gel, betamethasone valerate lotion and clobetasol
propionate ointment (Tosti et al., 2003; Camacho, 1997). They
Management of patients with alopecia areata is a challenging remain a very good option in children because of their painless
task as a number of risk factors have been implicated in its eti- application and wide safety margin.
ology. No definitive cure has been established, and treatment
has focused mainly on containing disease activity. 7.1.3. Systemic corticosteroids
Systemic corticosteroids do not constitute the first line treat-
7.1. Glucocorticoids ment for alopecia areata because of their extensive side effect
profile. The dosages necessary to maintain hair regrowth in
Topical and intralesional steroids have been the mainstay of AA are between 30 and 150 mg daily (Burton and Shuster,
therapy, and have been used as first line agents for the manage- 1975). Treatment course can range from 1 to 6 months, but
ment of the same. Glucocorticoids have been harnessed for prolonged courses should be avoided secondary to the numer-
their overarching anti-inflammatory effects for AA (Ross ous side effects of these drugs especially when children are trea-
and Shapiro, 2005). ted. Systemic steroids are thus not preferred in the treatment of
alopecia areata except for some cases as a short course only. Its
7.1.1. Intralesional corticosteroids side effect profile in conjunction with the long-term treatment
For circumscribed AA involving less than 50% of the scalp, requirements and high relapse rates make systemic corticoste-
intralesional corticosteroids are the first-line approach (Mada- roids a more limited option. Friedli et al. (1998) have also re-
ni and Shapiro, 2000). Triamcinolone acetonide in a concen- ported successful therapy with pulsed methylprednisolone
tration of 10 mg/ml is administered using a 0.5-inch long 30- (250 mg IV twice daily for three consecutive days) in patchy
gauge needle in multiple 0.1 mL injections approximately AA. Contraindications and side effects should however be dis-
1 cm apart (Pascher et al., 1970). Initial results of intralesional cussed at length with patients considered for this therapy.
Alopecia areata: A review 43
7.1.4. Oral mini pulse steroids satisfactory results (Galbraith, 1984). Adverse effects of topical
To avoid the side effects of daily steroids, pulse therapy was immunotherapy include pruritus, mild erythema, scaling, and
conceived.In a study conducted by Pasricha et al., betametha- postauricular lymphadenopathy. Reported undesired side ef-
sone oral mini-pulse therapy is a convenient and fairly effective fects include contact urticaria, postinflammatory hyper- and
treatment modality for extensive alopecia areata (Pasricha and hypo-pigmentation, erythema mutliforme, facial or eyelid ede-
Kumrah, 1996). However, it is proposed that randomized con- ma, fever, flulike symptoms, anaphylaxis,‘‘dyschromia in con-
trolled trials with standard therapies on a larger number of pa- fetti,’’ and vitiligo.
tients are required to give more insight into the efficacy and
safety of oral mini-pulse therapy for extensive alopecia areata. 7.5. PUVA
Oral mini-pulse therapy (OMP) with corticosteroids has been
successfully used for the treatment of alopecia areata with min- The use of PUVA (psoralen plus ultraviolet light A) is based
imal side effects. Persistent hiccups is a rare complication of on the concept that the mononuclear cells and Langerhans
oral and intravenous corticosteroid therapy (Dickerman and cells that surround the affected hair follicles may play a direct
Jaikumar, 2001). pathogenic role and that PUVA therapy can eradicate this
inflammatory cell infiltrate. Recently, Whitmont did a study
7.2. Minoxidil with 8-methoxypsoralen (8-MOP) (oral dose-0.5 mg/ kg) plus
UVA radiation at 1 J per square cm (J/cm2) and have demon-
First introduced as an antihypertensive agent, its side effect of strated complete hair regrowth in patients with AA totalis
hypertrichosis led to its use as treatment for various forms of (53%) and AA universalis (55%) and a low relapse rate among
alopecia. Minoxidil directly affects follicles by stimulating pro- these patients (21%) within a long period of follow up (means
liferation at the base of the bulb and differentiation above the 5.2 years) Whitmont and Cooper, 2003. In 2005, Mohamed
dermal papilla, independent of its vascular influences (Fiedler et al. did a large study (124 patients with AA and 25 patients
et al., 1990). Minoxidil has shown considerable results in the with AA totalis or universalis) (Mohamed et al., 2005). They
management of AA and it is believed that patients resistant used topical 8-MOP plus UVA radiancy at higher doses (8–
to minoxidil treatment often suffer from severe AA, AT or 42 J/cm2) and they found that 85% of patients from the AA
AU (Buhl, 1991; Fransway and Muller, 1988). Combination group had good or excellent response to the treatment, and
therapy of minoxidil 5% lotion and anthralin have been docu- 14 patients from AA U group had 50% hair regrowth. Side ef-
mented to show better results by few authors (Price, 1987). fects included slight erythema and painful burning in patients
who did not protect their scalp from sunlight after PUVA
7.3. Anthralin exposure. Recurrence of hair loss was noted in eight cases after
a period of 10 months to 2 years of treatment.
Anthralin exerts its effect through its irritant contact proper- The relatively simple procedure of PUVASOL therapy (Lo-
ties. It also acts through its immunosuppressive and anti- cal and systemic) because of good availability of solar radia-
inflammatory properties via the generation of free radicals tion, negligible side effects, encouraging results and non-
(Madani and Shapiro, 2000). Patients are instructed to apply availability of various other procedures and frequent treatment
0.5–1% anthralin cream to bare areas for 20–30 min daily over failures with these treatment schedules makes this procedure
2 weeks, gradually increasing daily exposure until low-grade better suited in the tropics. (Sharma et al., 1990)
erythema and pruritus develops, which when once achieved
is continued for 3–6 months (Ross and Shapiro, 2005). It is be- 7.6. Cyclosporine A (CsA)
lieved to be a suitable agent for children under 10 years of age
(Thappa and Vijayikumar, 2001). Adverse effects include scal- Cyclosporine A is a common antimetabolite drug used in post-
ing, staining of treated skin and fabrics, folliculitis, and regio- transplantation patients which exerts its effect via inhibition of
nal lymphadenopathy. T-cell activation. A common cutaneous side effect is hypertri-
chosis, which occurs in approximately 80% of patients, possi-
7.4. Topical immunomodulators bly as a result of prolongation of the anagen phase of the hair
cycle. It also decreases the perifollicular lymphocytic infil-
Topical immunotherapy relies on inciting an allergic contact trates, particularly the mean number of helper T cells (Taylor
dermatitis (ACD) by applying potent contact allergens to the et al., 1993) Successful use of systemic CsA in patients with AA
affected skin. It is believed that contact sensitizers act through has been conflicting as it is a nephrotoxic, hepatotoxic drug, it
immunomodulation of the skin and its appendages at several also causes gingival hyperplasia, headaches, tremors, and
different points. Dinitrochlorobenzene (DNCB) was the first hyperlipidemia (Gupta et al., 1990).
sensitizer used for the treatment of AA (Rosenberg and Drake,
1976). Other contact sensitizers used in alopecia areata are di- 7.7. Tacrolimus
phenyl-cyclo-propenone (DPCP) and squaric acid dibutyl ester
(SADBE). The only disadvantage of DNCB is its mutagenicity Tacrolimus is a topical calcineurin inhibitor that inhibits tran-
by Ames test. DNCB was however found to be non-carcino- scription following T-cell activation of several cytokines
genic when fed in large doses in rats, mice, guinea pigs and including interleukin-2, interferon-and tumor necrosis factor
man. Happle and Echternacht (1977), had a good response (Lawrence, 1998). Yamamoto et al. reported in their findings
with DNCB. Inosiplex, a synthetic drug that acts as an immu- that tacrolimus stimulated hair growth in mice (Yamamoto
nomodulating agent was used recently in cases of alopecia to- et al., 1994) although subsequent studies showed conflicting re-
talis and cell mediated immunodeficiency states with sults (Jiang et al., 1995).
44 S.S. Amin, S. Sachdeva
Garcia-Hernandez, M.J., 2000. CFM. Atypical clinical forms of Paus, R., Heinzelmann, T., Schultz, K.D., Furkert, J., Fechner, K.,
alopecia areata. In: Camacho Francisco, M.R., Price Vera, H. Czarnetzki, B.M., 1994. Hair growth induction by substance P.
(Eds.), Hair and its Disorders: Biology, Pathology, and Manage- Lab. Invest. 71, 134–140.
ment. Martin Dunitz, London, pp. 228–231. Price, V.H., 1987. Double-blind, placebo-controlled evaluation of
Gilhar, A., Kalish, R., 2006. Alopecia areata: a tissue-specific topical minoxidil in extensive alopecia areata. J. Am. Acad.
autoimmune disease of the hair follicle. Autoimmun. Rev. 5, 64–69. Dermatol. 16, 730–736.
Gupta, A.K., Ellis, C.N., Nickoloff, B.J., et al, 1990. Oral cyclospor- Price, V.H., Gummer, C.L., 1989. Loose anagen syndrome. J. Am.
ine in the treatment of inflammatory and noninflammatory Acad. Dermatol. 20, 249–256.
dermatoses. A clinical and immunopathologic analysis. Arch. Ragunatha, S., Inamadar, A.C., Palit, A., Sampagavi, V.V., Deshmukh,
Dermatol. 126, 339–350. N.S., 2008. Diffuse nonscarring alopecia of scalp: an indicator of
Happle, R., Echternacht, K., 1977. Induction of hair growth in early infantile scurvy? Pediatr. Dermatol. 25 (6), 644–646.
alopecia areata with DNCB. Lancet 2, 1002–1003. Raud, J., Lundeberg, T., Brodda-Jansen, G., Theodorsson, E., Hedq-
Hordinsky, M., Ericson, M., 2004. Autoimmunity: alopecia areata. J. vist, P., 1991. Potent anti-inflammatory action of calcitonin gene-
Invest. Dermatol. Symp. Proc. 9, 73–78. related peptide. Biochem. Biophys. Res. Commun. 180, 1429–1435.
Hordinsky, M., Lorimer, S., Worel, S., 1995a. Innervation and Rosenberg, E.W., Drake, L., 1976. Discussion of Dunaway DA.
vasculature of the normal human and alopecia areata hair follicle: Alopecia areata. Arch. Dermatol. 112, 256.
an immunohistochemical and laser scanning confocal microscope Ross, E.K., Shapiro, J., 2005. Management of hair loss. Dermatol.
study. In: Proceedings of the First Tricontinental Meeting of Hair Clin. 23, 227–243.
Research Societies. Brussels, Belgium. Ruiz-Doblado, S., Carrizosa, A., Garcia-Hernandez, M.J., 2003.
Hordinsky, M.K., Kennedy, W., Wendelschafer-Crabb, G., Lewis, S., Alopecia areata: psychiatric comorbidity and adjustment to illness.
1995b. Structure and function of cutaneous nerves in alopecia Int. J. Dermatol. 42, 434–437.
areata. J. Invest. Dermatol. 104 (Suppl.), 28–29, 28S–29S. Safavi, K.H., Muller, S.A., Suman, V.J., et al, 1995. Incidence of
Igarashi, R., Moroashi, M., Takeuchi, S., 1981. Immunofluorescence alopecia areata in Olmsted County, Minnesota, 1975 through 1989.
studies on complement components in the hair follicles of normal Mayo Clin. Proc. 70, 628–633.
scalp and of scalp affected by alopecia areata. Acta Derm. Venreol. Sharma, P.K., Jain, R.K., Sharma, A.K., 1990. PUVASOL therapy in
61, 131–135. alopecia areata. Indian J. Dermatol. Venereol. Leprol. 56, 301–303.
Jiang, H., Yamamoto, S., Kato, R., 1995. Induction of anagen in Sharma, V.K., Dawn, G., Kumar, B., 1996. Profile of alopecia areata
telogen mouse skin by topical application of FK506, a potent in Northern India. Int. J. Dermatol. 35 (1), 22–27.
immunosuppressant. J. Invest. Dermatol. 104, 523–525. Shimmer, B.P., Parker, K.L., 2001. Goodman’s and Gillman’s: the
Lawrence, I.D., 1998. Tacrolimus (FK506): experience in dermatology. Pharmacological Basis of Therapeutics. McGraw-Hill, New York
Dermatol. Ther. 5, 74–84. (pp. 1661–1663).
Bark-Lynn Lew, M.D., Min-Kyung Shin, M.D., Woo-Young Sim, Strober, B., Siu, K., Alexis, A., et al, 2005. Etanercept does not
2009. Acute diffuse and total alopecia: a new subtype of alopecia effectively treat moderate to severe alopecia areata: an open-label
areata with a favorable prognosis. J. Am. Acad. Dermatol. 60 (1), study. J. Am. Acad. Dermatol. 52, 1082–1084.
85–93. Tan, E., Tay, Y.-K., Goh, Ch.-L., et al, 2002. The pattern of
Madani, S., Shapiro, J., 2000. Alopecia areata update. J. Am. Acad. alopecia areata in Singapore – a study of 219 Asians. Int. J.
Dermatol. 42, 549–566. Dermatol. 41, 748–753.
Maria, Hordinsky, Marna, Ericson, 2004. Autoimmunity: Alopecia Tan, E., Tay, Y.K., Giam, Y.Ch., 2002. A clinical study of childhood
Areata. J. Invest. Dermatol. Symp. Proc. 9, 73–78. alopecia areata in Singapore. Pediatr. Dermatol. 19, 298–301.
McDonagh, A.J., Tazi-Ahnini, R., 2002. Epidemiology and genetics of Taylor, M., Ashcroft, A.T., Messenger, A.G., 1993. Cyclosporin A
alopecia areata. Clin. Exp. Dermatol. 27, 405–409. prolongs human hair growth in vitro. J. Invest. Dermatol. 100,
McMichael, A.J., 1997. The genetic epidemiol autoimmune pathogen- 237–239.
esis alopecia areata. J. Eur. Acad. Dermatol. Venereol. 9, 36–43. Thappa, D.M., Vijayikumar, M., 2001. Alopecia areata. Indian J.
Mohamed, Z., Bhouri, A., Jallouli, A., et al, 2005. Alopecia areata Dermatol. Venereol. Leprol. 67, 188, 188–188.
treatment with a phototoxic dose of UVA and topical 8- Tosti, A., La Placa, M., Placucci, F., et al, 1996. No correlation
methoxypsoralen. J. Eur. Acad. Dermatol. Venereol. 19, 552–555. between CMV and alopecia areata. J. Invest. Dermatol. 107, 443.
Odom, Richard B., Davidsohn, Israel, James, William D., Henry, John Tosti, A., Piraccini, B.M., Pazzaglia, M., et al, 2003. Clobetasol
Bernard, Berger, Timothy G., 2006. Clinical diagnosis by labora- propionate 0.05% under occlusion in the treatment of alopecia
tory methods. In: Elston, Dirk M. (Ed.), Andrews’ Diseases of the totalis/universalis. J. Am. Acad. Dermatol. 49, 96–98.
Skin: Clinical Dermatology. Saunders Elsevier. Trueb, R.M., 2010. Systematic approach to hair loss in women. Indian
Olsen, E.A., 2003. Hair, in Fitzpatrick’s dermatology in general Clin. Updat.-Dermatol. 2 (4), 284–297.
medicine. In: Freedberg, I.M. (Ed.). McGraw-Hill, New York, pp. van der Steen, P., Boezeman, J., Duller, P., Happle, R., 1992. Can
641–643. alopecia areata be triggered by emotional stress? An uncontrolled
Olsen, E.A., Hordinsky, M.K., Price, V.H., Roberts, J.L., Shapiro, J., evaluation of 178 patients with extensive hair loss. Acta Dermato.
Canfield, D., et al, 2004. National alopecia areata foundation. Venereol. (Stockh) 72, 279–280.
Alopecia areata investigational assessment guidelines. Part II. Wasserman, D., Guzman-Sanchez, D.A., Scott, K., Mc Michael, A.,
National Alopecia Areata Foundation. J. Am. Acad. Dermatol. 51, 2007. Alopecia areata. Int. J. Dermatol. 46, 121–131.
440–447. Whiting, D.A., 2003. Histopathologic features of alopecia areata: a
Pascher, F., Kurtin, S., Andrade, R., 1970. Assay of 0.2 percent new look. Arch. Dermatol. 139 (12), 1555–1559.
fluocinolone acetonide cream for alopecia areata and totalis. Whitmont, K., Cooper, A., 2003. PUVA treatment of alopecia areata
efficacy side effects including histologic study ensuing localized totalis and universalis: a retrospective study. Australas J. Dermatol.
acneiform response. Dermatologica 141, 193–202. 44, 106–109.
Pasricha, J.S., Kumrah, L., 1996. Alopecia totalis treated with oral Yamamoto, S., Jiang, H., Kato, R., 1994. Stimulation of hair growth
mini-pulse (OMP) therapy with betamethasone. Indian J. Derma- by topical application of FK506, a potent immunosuppressive
tol. Venereol. Leprol. 62, 106–109. agent. J. Invest. Dermatol. 102, 160–164.
Paus, R., 1996. Control of the hair cycle and hair diseases as cycling Yang, S., Yang, J., Liu, J.B., et al, 2004. The genetic epidemiology of
disorders. Curr. Opin. Dermatol. 3, 248–258. alopecia areata in China. Br. J. Dermatol. 151, 16–23.